This pioneering work highlights the potential of targeting CDKs with specific inhibitors like palbociclib to destabilize HIF1α, offering fresh avenues to impede the hypoxic response integral to tumor survival and proliferation. This evidence concerns the gene HIF1A and neoplasm.